The Institute is proud to team up with Ventri Clinical to drive new innovative medtech solutions to heart disease.
Professor Jason Kovacic, Executive Director of the Victor Chang Cardiac Research Institute, says: “We are committed to ensuring our research delivers not only new treatments, but new devices that address the world’s biggest killer.
“Being part of this broad network will improve health outcomes for all Australians by accelerating the development and testing of new technologies.”
Ventri Clinical, Australia’s Gateway for Cardiovascular Medtech Innovation, was launched earlier this year to connect and empower businesses, clinicians and professionals who conduct, contribute to, or support the successful testing and study of cardiovascular medical device innovations.
It’s facilitated by the Australian Cardiovascular Alliance (ACvA) and supported by MTPConnect, the Charles Perkins Centre at Sydney University, the Victor Chang Cardiac Research Institute and Hydrix.
“It’s incredibly exciting to have joined forces with the Victor Chang Cardiac Research Institute which has a proud history of delivering research that has transformed the treatment of heart disease,” says Anthony Murray, Director at Ventri Clinical.
“It is unique in Australia in that it has the combined forces of world class researchers and clinicians, as well as being home to state-of-the-art equipment and cutting-edge technologies through its Innovation Centre.
“Being able to access this expertise and technology will deliver drive better patient care and bolster Australia’s growing medical device industry.”
Ventri Clinical hopes to target sponsors of early-stage clinical development, pilot and post-market studies for the full range of cardiology technologies, including interventional devices, electrophysiology, diagnostics and echocardiography.
For all media enquiries and interview requests, please contact: